 The FDA has lifted the clinical hold on Rocket Pharmaceuticals Incs NASDAQ:RCKT Phase 1 trial of RP-A501 gene therapy for Danon Disease, allowing patient enrollment to resume. The hold was removed after the Company addressed the FDAs requests to modify the trial protocol and other supporting documents with revised patient selection and management guidelines. 